Company iBio, Inc.

IBIO

US4510337086

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:21:32 2024-04-26 pm EDT			5-day change	1st Jan Change
1.76 ^USD	+2.33%		+1.74%	+27.74%

Apr. 01	IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	CI
Mar. 28	Top Premarket Gainers	MT

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Number of employees: 26

Managers	Title	Age	Since
Martin Brenner CEO	Chief Executive Officer	54	21-01-17
Felipe Duran DFI	Director of Finance/CFO	45	21-03-31
Phan Dillon CTO	Chief Tech/Sci/R&D Officer	-	-
Matthew Luter CTO	Chief Tech/Sci/R&D Officer	-	-
Mike Jenkins COO	Chief Operating Officer	-	-
Stephen Kilmer IRC	Investor Relations Contact	-	-
Nick DeLong PRN	Corporate Officer/Principal	-	-
Lisa Middlebrook HRO	Human Resources Officer	-	20-12-31
Marc Banjak LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Chip Clark CHM	Chairman	56	21-08-22
Linda Armstrong BRD	Director/Board Member	61	20-10-13
Gary Sender BRD	Director/Board Member	62	20-10-13
James Hill BRD	Director/Board Member	78	08-07-31
Evert Schimmelpennink BRD	Director/Board Member	52	21-05-31
Alexandra Kropotova BRD	Director/Board Member	51	20-10-13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	8,515,226	8,500,031 ( 99.82 %)	0	99.82 %

Name	Equities	%	Valuation
Adar1 Capital Management LLC 9.269 %	789,293	9.269 %	3 M $
Opaleye Management, Inc. 7.633 %	650,000	7.633 %	3 M $
Lynx1 Capital Management LP 7.046 %	600,000	7.046 %	2 M $
Sabby Management LLC 2.076 %	176,748	2.076 %	717 597 $
Citadel Securities GP LLC 0.2981 %	25,387	0.2981 %	103 071 $
Warberg Asset Management LLC 0.2231 %	19,000	0.2231 %	77 140 $
UBS Securities LLC 0.2114 %	17,999	0.2114 %	73 076 $
Martin Brenner 0.1072 %	9,125	0.1072 %	37 048 $
BlackRock Institutional Trust Co. NA 0.0809 %	6,887	0.0809 %	27 961 $
Tower Research Capital LLC 0.0562 %	4,783	0.0562 %	19 419 $

iBio, Inc.

8800 HSC Parkway

77807, Bryan

+302 355 0650

http://www.ibioinc.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
IBIO, INC.	+25.55%	14.81M
NOVO NORDISK A/S	+25.17%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+14.57%	233B
NOVARTIS AG	+5.99%	201B
ROCHE HOLDING AG	-9.90%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals